Navigation Links
Key Caldolor(R) Orthopedic Data to Be Presented at American Academy of Orthopaedic Surgeons' Annual Meeting

NASHVILLE, Tenn., March 4 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that results from a clinical trial of Caldolor® (ibuprofen) Injection will be presented at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) in New Orleans, Louisiana.

A poster presentation of the study, entitled "A Multi-Center, Randomized, Double-Blind Placebo-Controlled Trial of Ibuprofen Injection (IVIb) for Treatment of Pain in Post-Operative Orthopedic Adult Patients," will be presented daily March 10 – 12 from 12:00 p.m. to 1:00 p.m. Neil Singla, M.D., Chief Executive Officer of Lotus Clinical Research, Inc., is the principal investigator of the study and Byron Kaelin, BSHS, RN, Manager of Clinical Operations at Cumberland Pharmaceuticals Inc., is the presenting author.

The data from this study demonstrates that pre- and post-operative administration of Caldolor is effective in treating pain and reducing morphine utilization in adult patients undergoing orthopedic surgery. No significant differences in adverse events were seen between Caldolor and placebo, including any that would suggest renal, cardiac or bleeding complications. Caldolor is the first and only injectable product approved in the United States to treat pain and fever.

Concurrent with the presentation, the poster will be available on Cumberland Pharmaceuticals' website at Copies also can be obtained by contacting the Company at 615-255-0068.

The AAOS Annual Meeting is the world's largest meeting of orthopaedic surgeons and allied health professionals and serves as a forum for sharing the latest information on orthopaedic treatments, advances and research. For more information, visit

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, including boxed warning, visit

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning and Kristalose® (lactulose) for Oral Solution, a prescription laxative. The Company also recently launched Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company completed the initial public offering of its common stock in August 2009. For more information on Cumberland Pharmaceuticals, please visit

SOURCE Cumberland Pharmaceuticals Inc.

Back to top



SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
2. New Caldolor(R) (ibuprofen) Injection Data to Be Presented at 44th American Society of Health-System Pharmacists Meeting
3. Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients
4. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
5. 2nd Annual Orthopedic Design & Technology Forum Returns April 28 to the FedEx Institute of Technology, University of Memphis
6. Hanger Orthopedic Group, Inc. Reports an Increase of 42.3% in Earnings Per Share, to $0.37 on a 10.6% Sales Increase, for the Fourth Quarter 2009
7. Hanger Orthopedic Group, Inc. Announces 2009 Year-End Earnings Release Conference Call
8. Medstrat Partners with Major Orthopedic Company
9. Hanger Orthopedic Group Increases Q4 2009 Sales and EPS Guidance
10. Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics
11. Reportlinker Adds Top Ten Worlds Leading Orthopedics Companies
Post Your Comments:
(Date:12/1/2015)... , Dec. 2, 2015  A combination of detailed ... the first time in the surgical planning for separation of ... annual meeting of the Radiological Society of North ... --> Conjoined twins, or twins whose bodies are connected, ... rates are low and separating them through surgery is extremely ...
(Date:12/1/2015)... , Dec. 1, 2015  A large study ... drug tamoxifen while taking an antidepressant found no increased ... today in The Journal of the National Cancer Institute. ... Tamoxifen is a commonly prescribed generic drug taken by ... developing a recurrence. Tamoxifen is recommended for five years, ...
(Date:12/1/2015)... Wash. and VANCOUVER , ... Committee (DMC) meeting, OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ... is continuing based on the pre-planned interim futility analysis ... review, no new safety issues were identified by the ... all analyses and final results are expected in the ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 02, 2015 , ... The National Association ... 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized ... networking organization exclusively for professional women, boasting 850,000 members and over 200 operating ...
(Date:12/1/2015)... ... December 02, 2015 , ... Ruth Pearson was struggling. ... flare-up. Unable to walk without assistance and quickly losing hope of recovering her former ... miracle happened. , Pearson was attending a women’s retreat when she experienced a particularly ...
(Date:12/1/2015)... ... December 02, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. ... the nation’s leading networking organization exclusively for professional women, boasting 850,000 members and, ...
(Date:12/1/2015)... NY (PRWEB) , ... December 02, 2015 , ... ... honors Jessica Clark as a 2015-2016 inductee into its VIP Woman of the ... NAPW is the nation’s leading networking organization exclusively for professional women, boasting 850,000 ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Trustify is ... in Washington, DC, hosted by Becky’s Fund, an organization dedicated to ending domestic violence. ... and control back to battered victims and survivors of domestic violence. Trustify is also ...
Breaking Medicine News(10 mins):